[January 21, 2016] |
|
Internationally Recognized Experts Appointed to SAB Biotherapeutics Scientific Advisory Board
SAB
Biotherapeutics, Inc. (SAB), a leading biopharmaceutical development
company, focused on advancing some of the most innovative molecular
genetics and human antibody technology in the world, today announced the
appointment of four internationally respected immunotherapy specialists
to its newly formed Scientific Advisory Board.
These globally recognized scientists and physicians will serve as a
strategic resource to SAB as it develops therapeutic applications for
its antibody production technology. SAB's DiversitAb™ Platform is a
next-generation technology for the production of fully human,
precision-targeted antibody therapeutics to treat a diverse range of
diseases. The proprietary DiversitAb technology is well advanced, having
proven effective on multiple targets in numerous scientific validations.
The platform is poised to produce antibody products for specific
targeted applications.
"We are honored to welcome these respected experts to join us in SAB's
mission to deliver diverse and highly effective antibody solutions,"
said Dr. Eddie Sullivan, President and CEO. "We are in the process of
commercializing our next-generation technology and ultimately delivering
the most relevant and impactful therapeutics. We look forward to the
skills, insights and wisdom of this new board in advancing these
initiatives."
The Board is comprised of a team of distinguished immunotherapy leaders
with diverse perspectives to provide valuable scientific and clinical
insights, in infectious disease, oncology, viral infections and
autoimmune disorders, as the Company advances antibody products through
clinical trials.
The members of SAB Biotherapeutics' new Scientific Advisory
Board include:
-
James
Robl, Ph.D., Scientist and Biotech Entrepreneur
James
Robl, Ph.D. is an internationally recognized scientist and
entrepreneur specialized in transgenic animals and cloning in cattle.
He is a former professor at the University of Massachusetts-Amhest
and founder of the project that led to the underlying technologies of
the DiversitAb Platform antibody production technology and Tc Bovine™.
Dr. Robl will serve as the Chairman of the advisory board.
-
Arturo
Casadevall, M.D., Ph.D., Johns Hopkins Bloomberg (News - Alert)
School of Public Health
Dr. Casadevall is an internationally
recognized expert in infectious disease research, with a focus on
fungal and bacterial pathogenesis and basic immunology of antibody
structure-function. He is a Bloomberg Distinguished Professor
of Molecular Microbiology & Immunology and Infectious Diseases at the
Johns Hopkins Bloomberg School of Public Health and Johns Hopkins
School of Medicine, and the Alfred and Jill Sommer Professor and Chair
of the W. Harry Feinstone Department of Molecular Microbiology and
Immunology at the Johns Hopkins Bloomberg School of Public Health.
-
Michael
Haller, M.D., MS-CI, University of Florida Medical
Center
Dr. Haller is Associate Professor of Pediatrics at the
University of Florida Medical Center and an active investigator in the
NIH funded Type 1 diabetes TrialNet and The Environmental Determinants
of Diabetes in Youth (TEDDY) study. He is the PI of promising studies
seeking to utilize combination therapies with antithymocyte globulin
(ATG (News - Alert)) and granulocyte colony stimulating factor (GCSF) in patients
with both recent onset and established Type 1 diabetes. In addition,
Dr. Haller served as the PI of a "first in man" study aimed at using
autologous umbilical cord blood stem cells as a potential therapy for
Type 1 diabetes.
-
Frederick
Hayden, M.D., University of Virginia School of
Medicine
Dr. Hayden is Richardson (News - Alert) Professor of Clinical
Virology in the Department of Medicine at the University of Virginia
School of Medicine. He is internationally recognized for his work with
the application of antiviral agents for the prevention and treatment
of respiratory viral infections, including influenza and rhinovirus
infections and other respiratory viral diseases. Dr. Hayden has
published over 300 peer-reviewed articles, chapters and reviews and
co-edited the textbook Clinical Virology. He works with the WHO-Global
Influenza Programme and as an advisor to the International Several
Acute Respiratory and Emerging Infection Consortium (ISARIC) as well
as serving as the Influenza Research Coordinator at Wellcome Trust and
as a consultant to the NIAID supported Southeast Asia Infectious
Diseases Clinical Research Network.
"SAB has a novel technology with the DiversitAb Platform that promises
important new therapeutic opportunities across a range of clinical
indications where significant unmet medical needs exist," said newly
appointed Board member, Dr. Arturo Casadevall. "I look forward to
working with the SAB team and these distinguished colleagues to pursue
these initiatives and bring new antibody products to patients and health
care providers around the world."
SAB Biotherapeutics, Inc. SAB Biotherapeutics, Inc. (SAB),
headquartered in Sioux Falls, South Dakota is an established,
biopharmaceutical company that is leading the science and manufacturing
of polyclonal antibody therapies. Utilizing some of the most advanced
antibody science in the world, SAB is delivering the world's first large
scale platform to create fully human, polyclonal antibodies. This
natural production platform holds the promise of treatment of public
health problems, rare conditions, long-term diseases and global pandemic
threats.
For more information visit: www.sabbiotherapuetics.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160121005808/en/
[ Back To TMCnet.com's Homepage ]
|